BioMarin Pharmaceutical Financial Statements (BMRN)
|
|
|
|
Report date
|
|
|
25.02.2022 |
31.03.2022 |
31.12.2022 |
27.02.2023 |
26.02.2024 |
|
31.10.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
1 846 |
|
2 096 |
2 096 |
2 419 |
|
735 958 |
|
Operating Income, bln rub |
|
|
-60.0 |
|
149.6 |
57.5 |
194.4 |
|
114 192 |
|
EBITDA, bln rub |
? |
|
48.0 |
|
165.7 |
267.5 |
310.3 |
|
114 348 |
|
Net profit, bln rub |
? |
|
-64.1 |
|
141.6 |
141.6 |
167.6 |
|
106 382 |
|
|
OCF, bln rub |
? |
|
304.5 |
|
175.9 |
175.9 |
159.3 |
|
387 435 |
|
CAPEX, bln rub |
? |
|
119.2 |
|
121.0 |
131.5 |
107.6 |
|
65 915 |
|
FCF, bln rub |
? |
|
185.3 |
|
54.9 |
44.4 |
51.6 |
|
321 520 |
|
Dividend payout, bln rub
|
|
|
0.000 |
|
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
|
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
1 458 |
|
1 946 |
1 571 |
1 746 |
|
444 721 |
|
Cost of production, bln rub |
|
|
470.5 |
|
483.7 |
483.7 |
514.9 |
|
188 930 |
|
R&D, bln rub |
|
|
628.8 |
|
649.6 |
649.6 |
746.8 |
|
185 475 |
|
Interest expenses, bln rub |
|
|
15.3 |
|
16.0 |
16.0 |
17.3 |
|
2 978 |
|
|
Assets, bln rub |
|
|
6 003 |
6 063 |
6 375 |
6 375 |
6 842 |
|
6 851 |
|
Net Assets, bln rub |
? |
|
4 271 |
4 391 |
4 603 |
4 603 |
4 952 |
|
5 413 |
|
Debt, bln rub |
|
|
1 079 |
1 080 |
1 083 |
1 083 |
1 134 |
|
602.7 |
|
Cash, bln rub |
|
|
1 014 |
1 056 |
1 292 |
1 292 |
1 074 |
|
930.4 |
|
Net debt, bln rub |
|
|
65.2 |
23.8 |
-208.5 |
-208.5 |
60.1 |
|
-327.8 |
|
|
Ordinary share price, rub |
|
|
88.4 |
77.1 |
103.5 |
103.5 |
96.4 |
|
79.7 |
|
Number of ordinary shares, mln |
|
|
182.9 |
|
185.3 |
185.3 |
187.8 |
|
190.4 |
|
|
Market cap, bln rub |
|
|
16 155 |
0 |
19 173 |
19 173 |
18 111 |
|
15 183 |
|
EV, bln rub |
? |
|
16 220 |
24 |
18 965 |
18 965 |
18 171 |
|
14 855 |
|
Book value, bln rub |
|
|
3 686 |
3 821 |
4 068 |
4 068 |
4 461 |
|
4 956 |
|
|
EPS, rub |
? |
|
-0.35 |
|
0.76 |
0.76 |
0.89 |
|
558.6 |
|
FCF/share, rub |
|
|
1.01 |
|
0.30 |
0.24 |
0.27 |
|
1 688 |
|
BV/share, rub |
|
|
20.2 |
|
22.0 |
22.0 |
23.7 |
|
26.0 |
|
|
EBITDA margin, % |
? |
|
2.60% |
|
7.90% |
12.8% |
12.8% |
|
15.5% |
|
Net margin, % |
? |
|
-3.47% |
|
6.75% |
6.75% |
6.93% |
|
14.5% |
|
FCF yield, % |
? |
|
1.15% |
0.00% |
0.29% |
0.23% |
0.29% |
|
2 118% |
|
ROE, % |
? |
|
-1.50% |
0.00% |
3.08% |
3.08% |
3.39% |
|
1 965% |
|
ROA, % |
? |
|
-1.07% |
0.00% |
2.22% |
2.22% |
2.45% |
|
1 553% |
|
|
P/E |
? |
|
-252.1 |
|
135.4 |
135.4 |
108.0 |
|
0.14 |
|
P/FCF |
|
|
87.2 |
|
349.0 |
432.2 |
350.7 |
|
0.05 |
|
P/S |
? |
|
8.75 |
|
9.15 |
9.15 |
7.49 |
|
0.02 |
|
P/BV |
? |
|
4.38 |
0.00 |
4.71 |
4.71 |
4.06 |
|
3.06 |
|
EV/EBITDA |
? |
|
337.7 |
|
114.5 |
70.9 |
58.6 |
|
0.13 |
|
Debt/EBITDA |
|
|
1.36 |
|
-1.26 |
-0.78 |
0.19 |
|
0.00 |
|
|
R&D/CAPEX, % |
|
|
527.4% |
|
537.0% |
493.8% |
694.0% |
|
281.4% |
|
|
CAPEX/Revenue, % |
|
|
6.46% |
|
5.77% |
6.28% |
4.45% |
|
8.96% |
|
| BioMarin Pharmaceutical shareholders |
